Intensity Therapeutics Secures $6.6 Million to Advance Innovative Cancer Treatment

Intensity Therapeutics, a leader in the development of intratumoral cancer therapies, has bolstered its financial position with a $6.6 million At-the-Market (ATM) offering. The sale of 19,868,658 shares at an average price of $0.3323 per share not only enhances the company's balance sheet but also extends the runway for its clinical trials into the latter half of 2026. Lewis H. Bender, the company's President and CEO, emphasized the strategic benefits of this financing round, citing its favorable pricing and efficiency in capital raising.

The company's flagship product, INT230-6, utilizes the proprietary DfuseRx℠ technology to deliver a powerful mix of anti-cancer agents directly into tumors. This innovative approach aims to achieve local tumor control while simultaneously activating the immune system against the cancer, offering a novel dual mechanism of action that avoids the immunosuppressive side effects typical of systemic chemotherapy. More details about this groundbreaking technology can be found at https://www.intensitytherapeutics.com.

Currently, INT230-6 is undergoing evaluation in several clinical trials, including a Phase 3 study for soft tissue sarcoma and a Phase 2 study for triple-negative breast cancer, in partnership with the Swiss Cancer Group. These trials are pivotal in assessing the therapy's efficacy and safety, with key metrics such as overall survival and pathological complete response under scrutiny. The successful funding round underscores the medical and investment communities' confidence in Intensity Therapeutics' approach to cancer treatment, highlighting the potential of intratumoral therapies to transform the landscape of oncology by offering new hope to patients with treatment-resistant cancers.